0 172

Cited 6 times in

Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome

Authors
 Hyun Seung Kim  ;  Tae-im Kim  ;  Jin Hyoung Kim  ;  Kyung Chul Yoon  ;  Joon Young Hyon  ;  Ko Un Shin  ;  Chul Young Choi 
Citation
 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, Vol.33(7) : 530-538, 2017 
Journal Title
 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 
ISSN
 1080-7683 
Issue Date
2017
Keywords
Restasis ; cyclosporin A ; dry eye ; nanoemulsion
Abstract
PURPOSE: Topical administration of the anti-inflammatory agent cyclosporin A (CsA) is recommended for long-term management of dry eye syndrome (DES), yet standard ophthalmic CsA preparations have been reported to be unstable. In this trial, the efficacy and safety of Clacier™ (based on a phase 3 study developed by Huons Co. Ltd.), a novel 0.05% CsA nanoemulsion formulation, are compared with those of the conventional Restasis® emulsion. METHODS: Patients with moderate-to-severe DES were randomly assigned to receive topical 0.05% CsA in the form of Clacier or Restasis, to be administered twice daily for 12 weeks. The primary efficacy outcome was the change from baseline in corneal fluorescein staining scores at week 12; changes at weeks 4 and 8 were secondary endpoints. Additional endpoints included score changes from baseline in nonanesthetic Schirmer's test I, tear breakup time, ocular surface disease index, and conjunctival staining. RESULTS: At week 12, corneal staining scores were improved in patients treated with Clacier and Restasis, with no significant difference between treatments (P = 0.41). Temporal conjunctival surface damage was significantly more ameliorated with Clacier treatment than with Restasis treatment (P = 0.034). Notably, tear film stability was improved more rapidly in Clacier patients at week 4 (P = 0.005) than in Restasis patients (P = 0.36). Improvements in tear production were comparable with both Clacier and Restasis treatments. Clacier did not increase the risk of adverse events as compared with Restasis. CONCLUSION: Treatment with Clacier alleviated clinical signs and symptoms of DES comparably to the commercially available Restasis, resulting in improved quality of life for patients. Clacier is an effective and safe therapeutic agent for DES.
Full Text
https://www.liebertpub.com/doi/abs/10.1089/jop.2016.0164
DOI
10.1089/jop.2016.0164
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Tae Im(김태임) ORCID logo https://orcid.org/0000-0001-6414-3842
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/165042
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse